I
schemic heart disease (IHD), also referred to as coronary artery disease (CAD), is the number one cause of mortality in the United States (1) . A significant percentage of patients who present for intermediate-to high-risk noncardiac surgery have IHD; 45% of U.S. veterans presenting for intermediate-to high-risk noncardiac surgery had IHD (2) , and Ͼ60% of patients who presented for vascular surgery had significant CAD (3) . Overall, approximately one third of the 40 million inpatient procedures that were performed in the year 2000 were on patients of Ͼ65 yrs of age (1) , a group with a high prevalence of IHD.
The association between history of IHD and postoperative cardiac morbidity and mortality was first reported by Butler et al. (4) in 1930. Practitioners were increasingly convinced of the association of preoperative IHD with poor postoperative outcomes; in 1972, Tarhan et al. (5) established the association. Subsequently, preoperative cardiac risk indices were proposed (6 -8) to identify patients with increased risk of perioperative cardiac events. This review will focus on current trends in preoperative cardiac risk assessment in patients scheduled to undergo noncardiac surgery and discuss the role of pharmacologic and invasive perioperative interventions that can ameliorate perioperative cardiac events that may affect postoperative management in critical care settings.
Preoperative Management
Preoperative Cardiac Risk Assessment. In 1977, Goldman et al. (6) proposed the landmark Cardiac Risk Index. Although not prospectively validated, this index was used extensively for preoperative cardiac risk assessment for the next two decades. In 1983, Jeffery et al. (9) demonstrated that the incidence of cardiac complications in patients who had undergone abdominal aortic procedures was higher than that predicted by the Cardiac Risk Index. Subsequently, other cardiac risk indices were proposed and adopted in clinical practice for cardiac risk stratification and determination as to the need for further testing (7, 8) . By the early 1990s, a confusing array of cardiac risk indices for preoperative cardiac risk stratification had been proposed ( Table  1) . Some of these strategies were expensive and time consuming. Therefore, in 1996, a 12-member task force of the American College of Cardiology and American Heart Association (ACC/AHA) published guidelines with respect to the perioperative cardiovascular evaluation of patients undergoing noncardiac surgery (10) . In March 2002, these guidelines were updated on the basis of new data (11) . The full revision of the update is available on the ACC Web site: http:// www.acc.org. The overriding theme of the original guidelines and the update is that "preoperative intervention is rarely necessary simply to lower the risk of surgery, unless such intervention is indicated irrespective of the perioperative context. No test should be performed unless it is likely to influence patient treatment." Although no prospective, randomized study has been conducted to prove the efficacy of these guidelines, some studies have suggested that there is utility in following them (12, 13) .
The ACC/AHA guidelines provide an eight-step algorithm for determining the need for preoperative cardiac evaluation. The first step assesses the urgency of surgery: the need for emergency surgery takes precedence over the need for additional workup. The second step assesses whether the patient has undergone revascularization (i.e., coronary artery bypass grafting [CABG] or a percutaneous coronary intervention [PCI] ). The third step determines if and when the patient un-derwent invasive or noninvasive coronary evaluation. If the patient had revascularization within the previous 5 yrs or had an appropriate coronary evaluation in the previous 2 yrs-with no subsequent deterioration of cardiac status-then further cardiac evaluation is not warranted.
The next five steps of the ACC/AHA guidelines integrate risk stratification according to clinical risk factors, functional capacity, and surgery-specific risk factors. Clinical risk factors-obtained by history, physical examination, and review of an echocardiogram-are grouped into three categories, namely: 1) major clinical predictors (unstable coronary syndrome, decompensated heart failure, significant arrhythmias, severe valvular disease) mandate intensive management, 2) intermediate clinical predictors (mild angina pectoris, previous myocardial infarction [MI] by history or pathologic Q waves, compensated or previous heart failure, diabetes mellitus [particularly insulin dependent], renal insufficiency) are well-validated markers of enhanced risk of perioperative cardiac complications, and 3) minor clinical predictors (hypertension, left bundle branch block, nonspecific ST-T wave changes, history of stroke) are recognized markers of CAD that have not been proven to independently increase perioperative risk (11) .
Functional capacity, also referred to as exercise tolerance, can be expressed in metabolic equivalent treadmill study (METs) levels. The oxygen consumption (VO 2 ) of a 70-kg, 40-yr-old man in a resting state is 3.5 mL·kg Ϫ1 ·min Ϫ1 or 1 MET. Perioperative cardiac and long-term risks are increased in patients unable to meet a 4-MET demand during most normal daily activities (poor functional capacity). These people may be able to do leisure activities (e.g., baking, slow ballroom dancing, golfing with a cart, walking at a speed of approximately 2-3 miles/hr), but they are unable to perform more strenuous (more than 4 METs) activity without developing chest pain or significant shortness of breath. Activities requiring more than 4 METs (good functional capacity) include climbing hills, ice skating, and running a short distance. Activities requiring Ն10 METs include participation in sports such as swimming, football, single tennis, basketball, and skating (11) .
Surgery-specific risk of noncardiac surgical procedures is graded as high, intermediate, or low. High-risk surgeries (emergent major operations particularly in the elderly, aortic and other major vascular surgery, peripheral vascular surgery, anticipated prolonged surgical procedures associated with large fluid shift or anticipated blood loss) are reported to have cardiac risk often of Ͼ5%. Intermediate risk surgeries (carotid endarterectomy, head and neck surgery, intraperitoneal and intrathoracic surgery, orthopedic surgery, prostate surgery) are reported to have cardiac risk generally at Ͻ5%. Low risk procedures (endoscopic procedure, superficial procedures, cataract surgery, breast surgery) are reported to have Ͻ1% risk of cardiac events (11) .
These ACC/AHA guidelines are being widely adopted and have significantly helped in clarifying and streamlining the preoperative cardiac assessment process. Institutions and practitioners can now conduct assessment and advise colleagues and patients in a consistent way rather than follow a variety of different cardiac risk indices. However, one should keep in mind the limitations of the guidelines. The guidelines have not been prospectively tested (14) , although there is evidence that they are helpful (12, 13 (12, 16) . Finally, it is difficult to generalize: regional and ethnic differences should also be taken into account, and the surgical risk categories also may be modified based on specific institutional results, which are highly dependent on surgical skills, anesthetic care, and nursing quality (17, 18) . Although debated, there is evidence that significant differences exist between care and outcomes at different institutions for the same surgical procedure (18 -21) . Once the patient has been identified as a candidate for further testing, he or she should be referred to a cardiologist or an internist. As evident in Table 2 , most patients with a history of CAD who have not been tested in the previous 2 yrs and have poor functional capacity likely will be referred for further testing before intermediate-or high-risk surgery. Although utility of preoperative stress testing has been questioned (22) (23) (24) , many consider it to be important in deciding further management strategy (11, 14) . Although some patients may be candidates for exercise stress testing, many are likely to have poor functional capacity and are referred for pharmacologic stress testing: stress echocardiography after dobutamine or atropine administration or a dipyridamole thallium nuclear imaging study. Both dobutamine stress echocardiography and dipyridamole thallium nuclear imaging have high negative predictive value (94% and 88%, respectively). The positive predictive value of dobutamine stress echocardiography is better (67% vs. 37%) (16, 25) , and dobutamine stress echocardiography is more physiologically representative of the postoperative state (16) . However, dipyridamole thallium nuclear imaging effectively detects significant coronary occlusion and myocardium at risk and is probably a better test in patients who have baseline left bundle-branch block (11) . A more detailed discussion of which test is the most appropriate test for preoperative risk stratification is beyond the scope of the present discussion and has been reviewed thoroughly elsewhere (11, 16, 25) .
Preoperative Management Strategy After Preoperative Cardiovascular Assessment. Once the patient with IHD has been identified and the degree of IHD quantified by either invasive or noninvasive testing, three therapeutic options are available before elective noncardiac surgery: 1) revascularization by surgery (CABG); 2) revascularization by PCI; and 3) optimized medical management, typically with beta-blockers or alpha-2 agonists. These treatments have effectively improved long-term outcomes in nonoperative settings. Hence, many patients with significant IHD who present for noncardiac surgery likely would be candidates for one or more of the abovementioned therapies, regardless of whether they are scheduled for surgery. However, it many not be advisable to intervene preoperatively (except with pharmacologic therapy). Coronary revascularization should be guided by the patient's cardiac condition (i.e., is there unstable angina, left main CAD, three-vessel disease, decreased left ventricular function, and left anterior descending artery disease?) and by the added risk of the coronary intervention and the potential consequences of delaying the noncardiac surgery for recovery after the intervention (11) .
The Coronary Artery Surgery Study (26) study showed that patients who had coronary revascularization before majorrisk surgery did better postoperatively. The perioperative mortality rate was twice as high in patients who were medically managed than in those who had preoperative CABG surgery (3.3% vs. 1.7%, p Ͻ .05). Similar beneficial results were noted in a selected group of patients in the Bypass Angioplasty Revascularization Investigation (27) trial and in evaluation of a random sample of Medicare beneficiaries (28) . However, patients would have had to survive CABG surgery before they could undergo noncardiac surgery. For CABG surgery to be beneficial, the institutional risk for noncardiac surgery alone should be greater than the combined risks of coronary catheterization, coronary revascularization, and the subsequent noncardiac surgery. The decision analysis of Mason et al (29) showed that proceeding with vascular surgery was better than undergoing CABG surgery before elective noncardiac vascular surgery. On the other hand, Landesberg et al. (30) showed that long-term mortality in patients who underwent CABG surgery before the vascular surgery was significantly improved at 5 yrs compared with patients who did not have CABG surgery (74.3% vs. 53.2%, p ϭ .006). Interestingly, there was no significant difference in the first 30-day outcome between the two groups (98.7% vs. 97.8%). This shows that short-term mortality is not affected by preoperative revascularization; only long-term outcome is improved. Hence, the indications for coronary revascularization are aimed primarily at improving long-term survival and outcome and thus are the same as in the nonoperative setting (unstable angina, left main CAD, three-vessel disease, decreased left ventricular function, and left anterior descending artery disease).
Initial evaluations of PCI revealed that patients who underwent angioplasty before elective noncardiac surgery had better outcomes (31) (32) (33) (34) . However, angioplasty is now often accompanied by stenting, with postprocedure antiplatelet therapy to prevent acute coronary thrombosis and maintain long-term patency of the intervened vessel. Two recent reports strongly suggest that elective noncardiac procedure surgery should be delayed for 4 -6 wks after PCI with stenting. Kaluza et al. (35) reported eight deaths, seven MIs, and 11 major bleeding episodes in a cohort of patients underwent noncardiac surgery within 40 days after stent placement. All deaths, MIs, and 8 of 11 bleeding episodes occurred in patients who had stent placement within 14 days. More recently, Wilson et al. (36) reported on 207 patients: eight had MIs and six died. All myocardial events or deaths occurred in patients who had PCI and stenting within 6 wks of noncardiac surgery, and these events were attributed to stent thrombosis. The authors concluded that it was prudent to delay elective noncardiac surgery for 6 wks after PCI to allow for complete endothelialization of the stent and completion of aggressive antiplatelet therapy with GIIb/IIIa inhibitors (36) . The recent introduction of drugreleasing stents may obviate the need for such prolonged systemic anticoagulation and thus improve outcomes in patients who undergo surgery shortly after stent placement.
Several pharmacologic agents have been used to reduce perioperative cardiac injury, primarily because they have demonstrated pharmacologic efficacy in the management of coronary ischemia in the nonsurgical setting. Nitroglycerine was an obvious choice initially. As in the nonoperative setting, it may be helpful in the management of active perioperative ischemia. However, prophylactic use of nitroglycerine has not been shown to be efficacious in reducing perioperative morbidity and mortality (37) . Perioperative use of beta-blockers has been shown to be efficacious in reducing perioperative morbidity and mortality (38 -41) . The clinician should recognize that the strongest evidence for efficacy of perioperative beta-blockers is based on studies with small numbers of patients (42, 43) . Nonetheless, the ACC/AHA guidelines recommend initiating beta-blockers as early as possible before high-risk surgery and titrating heart rate to 60 beats/min (11). Auerbach and Goldman (40, 44) have recommended perioperative betablocker use in a larger range of patients (Table 3) . Their decision tree recommends the use of perioperative betablockers in the following patients: 1) in patients with one or more Revised Cardiac Index risk factor, despite a negative stress test; and 2) in patients with two minor risk factors, even with good functional status or negative noninvasive stress test. In other patients, pharmacologic therapy likely would not be sufficient. Even if they receive beta-blockers, patients scheduled for vascular surgery who have three or more clinical risk factors and significant myocardium at risk are still at appreciable risk of sustaining perioperative MI or death (45) (42) .
Questions regarding perioperative beta-blocker initiation and duration, choice of agent, and target heart rate are still unresolved. Controversy also persists as to the efficacy of acute perioperative betablocker therapy vs. chronic beta-blocker therapy (46 -49) . Moreover, despite widespread dissemination of the data as to the potential efficacy of beta-blockers, many patients do not receive them before surgery. In a recent analysis at our institution, preoperative beta-blocker use was 50% in patients who were scheduled to undergo major-to intermediate-risk vas- cular surgery (50) . Furthermore, if a heart rate of Ͻ60 beats/min was considered a marker of adequate beta-blocker therapy, only 17% of the patients were noted to be adequately beta-blocked preoperatively (50) . Institutional protocols need to be developed to improve and standardize perioperative beta-blocker use among the caregivers throughout the preoperative, intraoperative, and postoperative periods (51). These not only should take into account the indications for such therapy but also the potential adverse effects, alone or in the context of other medications, including hypotension, bradycardia, syncope, stroke, bronchospasm, and allergic reactions. By virtue of their central action, alpha-2 agonists have analgesic, sedative, and sympatholytic effects. A study of 1,897 patients with established CAD did not show a significant difference in cardiac morbidity and mortality between patients treated with the alpha-2 agonist mivazerol and the control group (52); however, post hoc analysis in a subset of vascular patients showed improved outcomes in treated patients. Hence, in patients in whom beta-blockers are contraindicated, alpha-2 agonists may be considered as an alternative to decrease perioperative cardiac injury.
The evidence with respect to other pharmacologic agents is less clear. A meta-analysis by Wijeysundera and Beattie (53) suggested that calcium channel blockers are efficacious in reducing perioperative cardiac morbidity and mortality. However, Stevens et al. (41) did not find a significant beneficial effect of calcium channel blockers in this context, and trials in the nonoperative setting have raised questions about their efficacy (54) .
It is likely that other agents with beneficial effects in the nonoperative setting, such as angiotensin-converting enzyme inhibitors, statins, and aspirin, may prove to be beneficial perioperatively. Recently, a retrospective analysis by Poldermans et al. (55) in patients who underwent vascular surgery indicated that statins improved long-term outcome.
Intraoperative Management
Although the goals of intraoperative management (e.g., stable hemodynamics, normothermia, and avoidance of significant anemia) are generally agreed on, it has been difficult to determine whether any particular anesthetic or monitoring technique is superior in this regard. As long as intraoperative management is guided by sound physiologic goals, the outcomes in terms of perioperative cardiac morbidity are not appreciably different among current anesthetic techniques or monitoring modalities.
Some reports have suggested that regional techniques may be advantageous, but others have not confirmed this (56, 57) . Potential benefits of a regional anesthetic include better pain control (58, 59) and decreased prevalence of deep vein thrombosis in patients who undergo lower limb orthopedic procedures (60, 61) . However, the prevalence of postoperative cardiac morbidity and mortality does not seem to be significantly different between general and regional anesthesia.
The issue of monitoring is even more difficult to evaluate, especially invasive monitoring (62) . Although it is important to monitor hemodynamic indices and maintain them within a narrow range, it is difficult to prove that the presence of a particular monitor significantly alters morbidity or mortality. This is highlighted by the persistent controversy over the use of a pulmonary artery catheter. Proponents cite the rationale for diagnosis and titration of treatment; opponents cite lack of data supporting its use and the risk of complications. In a study involving 1,994 patients, Sandham et al. (63) demonstrated no significant difference in outcome in high-risk surgical patients monitored with pulmonary artery catheter vs. central venous catheter (mortality, 7.8% vs. 7.7%, respectively). Moreover, they noted a higher rate of pulmonary embolism in the pulmonary artery catheter group (p ϭ .004). However, one should keep in mind the limitation of the study. If mortality is considered the primary outcome, it would require 14,240 patients to be randomized to detect a difference of 20% between the groups with 90% power (64) . The ultimate decision to employ a particular monitor is significantly influenced by case-specific factors such as underlying disease, physician availability and expertise, and surgical and technical considerations.
Beta-blockers have been used as intraoperative therapeutic agents to control hemodynamics. Some studies investigating their prophylactic role have demonstrated decreased intraoperative ischemia. Hemodynamic goals for intraoperative therapy with beta-blockers are far from clear, and potential interactions with anesthetics (which commonly cause myocardial depression and vasodilatation) must be taken into account. Poldermans et al. (42) set their goals to maintain intraoperative heart rate at Ͻ80 beats/min; however, they did not report the intraoperative values obtained in their patients. The general consensus seems to be that if beta-blockers are indicated perioperatively, they should not only be given intraoperatively. As noted above, they typically should be initiated postoperatively and, except in the presence of significant contraindications, should be continued postoperatively.
Postoperative Management
Although significant advances have been made in researching and refining preoperative evaluation and management strategies, evidence-based strategies that can specifically be adopted in the postoperative period to improve outcomes still need to be developed. Our understanding of the pathophysiology of perioperative MI is largely based on the information in the nonoperative setting.
Pathophysiology of Perioperative MI. It has been estimated that each year, 50,000 patients undergoing elective surgery suffer an acute MI (65) . The mortality after perioperative MI has been quoted to be as high as 40 -50% (65) . The prevalence of perioperative cardiac injury is a cumulative result of the patient's preoperative medical status, the specific surgical procedure, expertise of the surgeon, and the overall medical care at a particular institution. It also depends on the diagnostic criteria used to define an MI. Earlier observations suggested that most postoperative MIs tend to occur on the third postoperative day (5, 66 -68) ; however, recent data suggest that most MIs tend to occur within the first 48 hrs (69). This discrepancy is thought to be related to the diagnostic criteria that were used in older studies (i.e., late-occurring MIs are predominantly Q-wave infarctions, whereas earlier MIs are non-Q-wave) (70) .
In the past decade, significant advances have been made in the understanding of the pathophysiology and diagnosis of MI. Atherosclerosis is no longer considered a "passive plumbing problem" with clogging of the arteries by lipids (71) . It is now accepted as an active inflammatory process with an undulating course (71) . Almost all MIs in nonoperative settings result from coronary atherosclerosis with superimposed coronary thrombosis (71) . A similar mechanism may be responsible for perioperative MIs, with exacerbation by the acute stresses associated with surgery (72) . Endothelial injury at the site of a plaque triggers cascade of platelet aggregation and release of mediators, including thromboxane A2, serotonin, adenosine diphosphate, platelet activating factor, thrombin, tissue factor, and oxygen-derived free radicals. Aggregation of platelets and activation of inflammatory and noninflammatory mediators potentiate thrombus formation and lead to dynamic vasoconstriction distal to the thrombus formation. The combined effects of dynamic and underlying narrowing cause ischemia and possibly infarction. In the postoperative period, changes in blood viscosity, catecholamines, cortisol, endogenous tissue plasminogen activator, and plasminogen activator inhibitor create a prothrombic state. Furthermore, changes in heart rate and blood pressure can increase propensity to plaque fissuring and endothelial damage. In combination, these factors can precipitate harmful thrombus formation in an atherosclerotic vessel (Fig.  1) , with the development of ST elevation or Q waves. Alternatively, Landesberg (73) suggested that most perioperative MIs are not associated with ST elevation. Instead, they are preceded by a significant duration of ST depression and tachycardia. This may indicate that the injury develops as a consequence of increased demand (increased blood pressure and heart rate) in the context of underlying compromised perfusion.
Challenges in Diagnosis of Perioperative MI. In 1979, the World Health Organization developed criteria for diagnosis of acute MI (74) that required the presence of at least two of the following elements: 1) ischemic-type chest pain, 2) evolutionary changes on serially obtained electrocardiographic tracings, and 3) rise and fall of cardiac markers (which at the time was creatine kinase/myocardial muscle creatine kinase isoenzyme [CK/ CK-MB]). However, one third of patients do not present with classic chest pain; and it has been estimated that as many as 95% of postoperative ischemic episodes are silent and chest pain free (65). Badner et al. (69) reported only a 17% rate of chest pain in patients who sustained a perioperative MI. In addition, 25% of the electrocardiograms obtained postoperatively are considered nondiagnostic. Further complicating diagnosis, nonspecific changes on the electrocardiogram, newonset arrhythmias, and noncardiacrelated hemodynamic instability can obscure the clinical picture of acute coronary syndrome in the postoperative period. Thus, it has been more difficult to define the criteria for perioperative MI because two out of the three elements are either not frequently present or not useful (75) .
In the nonoperative setting, measurement of cardiac-specific troponins now plays a significant role in the diagnosis of MI. This has prompted revisions of the evaluation and management of acute coronary syndromes (75) (Fig. 2) . Although there is inconsistency with respect to interpretation of troponin values, most studies highlight the utility of cardiac troponins in the diagnosis of perioperative MI (69, 76 -86) (Table 4) . They show increased sensitivity of troponins to myocardial injury that is not normally sufficient to cause CK-MB elevation, chest pain, or electrocardiographic abnormalities (79, (82) (83) (84) (87) (88) (89) . It is increasingly being recognized that, as in the nonoperative setting, an acute increase in troponins above the cutoff for the assay should be considered an MI in the perioperative setting. However, the association between perioperative ischemia and the rise in cardiac troponin levels has not been conclusively proven. Neill et al. (81) and Rapp et al. (80) were unable to demonstrate the association between ischemia by Holter and rise in cardiac troponins. On the other hand, Landesberg et al. (85) reported a good correlation between duration of ischemia and the rise in cardiac-specific troponin I. It also should be noted that the implications and clinical relevance of increases in troponins below the established cutoffs are still being investigated. First, should a small increase in troponin be considered a marker of myocardial ischemia or subclinical myocardial injury? Second, if present, are the small postoperative increases clinically relevant?
As is the case for nonsurgical patients, there is a significant association between increased troponin levels with poor short-and long-term outcomes in surgical patients. Lee et al. (77) and Lopez- Jimenez et al. (78) have shown that increased levels of troponins translate to poor short-and long-term outcomes postoperatively (cardiac death, MI, myocardial ischemia, congestive heart failure, cardiac arrhythmias, cerebrovascular accident). Even minor cardiovascular complications (uncontrolled hypertension, palpitations, increased tiredness or shortness of breath) were correlated to increased levels of cardiac-specific troponin T). Kim et al. (86) showed that in patients who underwent vascular surgery, those with cardiac-specific troponin I levels of Ͼ1.5 ng/mL had a six-fold increase in mortality at 6 months and a 27-fold increase in the risk of MI within 6 months. Landesberg et al. (90) evaluated a cohort of 447 patients who underwent major vascular procedures and concluded that increases in postoperative CK-MB and troponins, even at low cutoff levels, were independent and complementary predictors of long-term mortality. This suggests that the increase in cardiac troponins postoperatively, even in the absence of clear cardiovascular signs and symptoms, portends poor long-term outcome and that it is not simply a manifestation of an overly sensitive assay. Therapeutic Interventions. The benefits of coronary revascularization immediately after noncardiac surgery have been studied in only a limited number of settings (11) . The practice of carotid endarterectomy either concurrently with CABG surgery or immediately before CABG surgery is well documented; a significant difference between the two techniques has not been established (91, 92) . The value of PCI postoperatively after noncardiac surgery has not been addressed, largely because of the need for antithrombotic agents postprocedure.
Any clinical situation that leads to prolonged and significant hemodynamic perturbation can stress the heart. In patients with IHD who already have limited cardiac reserve or impaired coronary blood flow, prolonged and significant demand for increased cardiac output can lead to myocardial morbidity and mortality. Although most cardiac events happen within the first 48 hrs, delayed cardiac events (within the first 30 days) still happen and could be the result of secondary stresses. Development of pain, respiratory failure, sepsis, or hemorrhage can lead to increased myocardial oxygen demand. The resulting oxygen supply-demand imbalance in patients with IHD can lead to myocardial ischemia, injury, infarction, or death. The aforementioned hemodynamic changes may be ameliorated with beta-blockers. It is imperative that patients receiving these drugs preoperatively continue to receive them postoperatively. Two studies have suggested that starting the drugs postoperatively can decrease cardiac ischemia (93, 94) . However, it is not clear whether instituting beta-blockers postoperatively will achieve the benefits of initiating them preoperatively and continuing them into the postoperative period (42, 43) .
Prevention of hypovolemia and hypotension are universal goals in postoperative patients. It is important not only to maintain adequate intravascular volume but also to maintain adequate hemoglobin. Although an animal study suggests that myocardial dysfunction and ischemia occur earlier and to a greater degree in the context of anemia (95) , human data are inconsistent (96) . In two cohort studies, moderate anemia was poorly tolerated in perioperative patients and critically ill patients with cardiovascular disease (97, 98) . Wu et al. (99) showed that short-term mortality in elderly patients was lower in patients who received blood transfusion after acute MI. Nelson et al. (97) showed that a hematocrit of 28% was the best threshold; morbidity increased in patients with values below this level. Conversely, the TRICC trial (Transfusion Requirement in Critical Care) was not able to demonstrate a significant difference in 30-day mortality between patients who were "liberally" transfused (average hemoglobin, 10.7 g/dL) vs. the "restrictive" group (transfused only if hemoglobin decreased to Ͻ7 g/dL; average hemoglobin, 8.5 g/dL) (100). Furthermore, an observational study by Vincent et al. (101) demonstrated decreased mortality in patients who did not receive a transfusion.
There is a lack of consensus as to the fluid of choice when non-hemoglobincontaining solutions are indicated. The controversy regarding the choice of fluid (colloid vs. crystalloid and the type of colloid or crystalloid) for resuscitation is still ongoing. A meta-analysis did not detect significant differences between types of fluids (102) . Hence, for patients with IHD, a specific fluid cannot be advocated.
Timing of weaning and extubation in surgical patients is another much debated aspect of care for which there is no one protocol that works for all patients. Early extubation is possible in many patients, as long as they fulfill the criteria for extubation (weaning variables, appropriate mental status, adequate hemodynamics, adequate hemoglobin, and adequate temperature). During prolonged intubation and subsequent extubation, there can be significant hemodynamic stress (103); wakefulness and hemodynamic stability need to be appropriately balanced. Many patients with IHD become ischemic during weaning (103) because of increased heart rate and ratepressure product. Such hemodynamic perturbations should be managed with diligence and acute pharmacologic therapy (e.g., beta-blockers).
CONCLUSIONS
Due to changing demographics, increasing numbers of patients with IHD are presenting for noncardiac surgery, and the risks of perioperative morbidity and mortality are significant. Structured management protocols that help assess, diagnose, and treat patients with IHD preoperatively are likely to decrease postoperative morbidity and mortality, but they clearly will not be applicable to all patients. Augmented hemodynamic control with beta-blockers or alpha-2 agonists can play an important role in improving outcomes in many patients with IHD, and preoperative coronary revascularization may be of value in selected patients. Intraoperative anesthetic management that minimizes hemodynamic perturbations is important; however, choice of a particular technique typically is not critical. Of critical importance is the postoperative management of the patient. Postoperative myocardial injury should be identified, evaluated, and managed aggressively. Secondary stresses such as sepsis, extubation, and anemia that can increase demand on the heart should be treated or minimized. Clearly, optimal care of the patient with IHD entails closely coordinated assessment and management throughout the preoperative, intraoperative, and postoperative phases if one is to optimize short-term and long-term outcomes.
